Market Scenario 

COPD & asthma diagnostic and monitoring devices market was valued at US$ 7.77 billion in 2023 and is projected to hit the market valuation of US$ 16.12 billion by 2032 at a CAGR of 8.45% during the forecast period 2024–2032.

Chronic Obstructive Pulmonary Disease (COPD) and asthma are some of the most prevalent diseases in the globe. Every year chronic obstructive pulmonary diseases claim over three million lives, which makes it the third leading cause of death after heart diseases and stroke. Approximately 300 million people suffer from asthma that causes about 400,000 deaths annually. The World Health Organization (WHO) is clear on how to address this gap in attention and or resources as it adds that asthma accounts for almost 10% of all deaths associated with noncommunicable diseases, every year. According to the Centers for Disease Control and Prevention (CDC) statistics, as many as 1.5 million emergency department visits due to asthma occur annually in the United States of America.

COPD tends to be a higher health risk in areas with high tobacco intake and air quality restrictions. Within this context, for example, China COPD & asthma diagnostic and monitoring devices market has over 100 million estimated figures of pre and post diagnosed people with COPD. When it comes to asthma, India has one of the largest populations suffering from the disease, with figures exceeding 30 million people. The most vulnerable groups are children and older people and out of these groups, children have asthma as the most prevalent chronic ailment with about 10 million people worldwide below 15 years suffering from this disease. At least 70 million persons in the United States and Europe suffer from smoking related COPD according to WHO. The CDC reports that asthma is responsible for more school absences than any other chronic disease with over 13 million school days lost each year to this condition in America alone.

The growing demand for COPD & asthma diagnostic and monitoring devices market can be attributed to the technological advancement and rising occurrence of the disease. Reportedly, this market has reached a total of $ 8 billion in the second half of 2024 due to the continuous development in the sphere of digital health devices. Spirometers, peak flow meters and pulse oximeters are in rising demand with more than one billion tests of spirometry done every year by countries. It is also possible to do remotely over 50 million of such assessments per year with the combination of telemedicine and mobile health apps. The players in the market are focusing on the use of AI in the diagnosis with more than US$ 500 million worth of investments made last year to improve the accuracy and performance of the devices. New opportunities are also emerging for market development due to the rising burden of respiratory diseases in the developing parts of the World such as southeast Asia and Africa. 

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Increasing Prevalence of Respiratory Disorders Spurs Demand for Diagnostic Monitoring Devices

Respiratory diseases are a major factor driving the growth of the COPD & asthma diagnostic and monitoring devices market. It was estimated that as of 2023 around 500 million people were suffering from chronic respiratory diseases, the most prevalent ones being COPD and asthma. As cities such as Delhi and Beijing become more urbanized and industrialized, the level of pollution has increased, with some parts of these cities having pollution level over seven times higher than WHO acceptable levels. The occurrence of COPD is made worse by smoking, accounting for more than 1.1 billion smokers around the world. According to the World Health Organization, death caused by respiratory diseases is still among the foremost globally and therefore development of good diagnostic devices is essential.

Healthcare spending on respiratory illnesses meets this growing demand and accounts for about $150 billion in the year 2023 worldwide. There have been over 10 million annual admissions due to Asthma and COPD seeking better diagnosis, which shows a gap in the COPD &asthma diagnostic and monitoring devices market. The absence of prompt detection resulted in high death rates, which estimated 3 million people die from the undiagnosed disease every year. Hence, there is vast potential for the companies to provide advanced level diagnostic and monitoring devices for the market. The global respiratory diagnostic devices market is estimated to have a surge of $10 billion over the next 5 years due to these factors.

Trend: Growing Preference for Portable and User-Friendly Home-Based Respiratory Monitoring Solutions

There are trends developing in past years across countries for developing portable and easy to use technologies for the home-based respiratory management. As per the reports on the COPD & asthma diagnostic and monitoring devices market, in 2023 the market registered the selling of 10 million home-based spirometers reflecting an overwhelming demand among the consumers to treat respiratory ailments at home. These tools have become especially useful in regions of North America and Europe where the healthcare systems are under pressure. Approximately 100 million people needed constant monitoring and these figures brought about a rise in the interest towards portable devices which enable self-management with less frequent hospital visits in 2023.

The demand for home-based monitoring systems in the COPD & asthma diagnostic and monitoring devices market is projected to grow bigger by US$ 3 billion within the next three years due to the drive from technology and growing respiratory health awareness. This change was already noticeable when in 2023, the number of mobile health applications for respiratory monitoring was approaching 50 million downloads. With mobile phones and the internet, people have also been able to sell these devices and accordingly, e-business accounted for 50% of the sales made in the respiratory device industry. On top of that, the provision of reimbursement for the home monitoring solutions has also taken a turn for the better, as there are 100 insurances offering such reimbursement around the world. This pattern is likely to persist as customer demand for patient’s care health solutions and digitalization in healthcare goes on.

Challenge: High Costs of Advanced Diagnostic Devices Hinder Widespread Adoption in Low-Income Areas

The exorbitant cost of diagnostic devices is another global issue that needs to be addressed in the COPD & asthma diagnostic and monitoring devices market. The $2,000 average price of a complex diagnostic device was prohibitory in 2023 to many healthcare centers especially those located in the developed countries. This is rather worrying as more than 700 million people around the globe survive on less than a dollar and are therefore unable to afford basic medical care. This is the case of the rich and poor poise where Nigeria and India emerge, only 40 % of the rural health posts in these countries possess maximum basic respiratory diagnostic devices. Unaffordability has brought about a delay in both diagnosis and treatment which have subsequently decreased the health outcomes.

Various organizations and international non-profit agencies have taken action against this challenge in the COPD &asthma diagnostic and monitoring devices market by spending $500 million on healthcare infrastructure and the accessibility of diagnostic devices in low-income countries. However, such demand does not satisfy the existing supply, with an additional estimated demand for an additional 5 million diagnostic devices needed in such regions. Tremendously frustrating the advancement of the diagnostic market is the failure of local administrations to stimulate the manufacturing and placement of inexpensive diagnostic apparatuses for the populace. The restricted ophthalmic diagnostic facilities affect such healthcare providers as nurses, where only 20% of rural medical personnel receive a proper count in school for the management of respiratory diseases. An increase in the attainment of such devices will need a joint effort from the several players in the public and private sectors to come up with new cost-effective and high standard diagnostic devices to be used by people from poor backgrounds.

Segmental Analysis 

By Product

The diagnostics devices hold more than 67% share of COPD & asthma diagnostic and monitoring devices market revenue and are expected to remain in the leading position in the future as well. Some of the reasons for this prominence include an increasing number of people having respiratory diseases. For example, The WHO estimates that about 200 million people are suffering from COPD, which causes about 3 million deaths a year. WHO estimates that 262 million people are affected by asthma with this illness leading to the deaths of 461,000 each year. Politically or socially backward countries are more affected, Air pollution has reached hazardous levels in several cities like Delhi. Furthermore, the ever-growing infirm elderly population also matters since older individuals tend to be suffering more chronic respiratory issues than younger ones. In 2023, it is recorded that the number of the world elderly population aged 65 and older stands to 703 million making a case for respiratory health management.

The main end users of COPD & asthma diagnostic and monitoring devices market are hospitals, clinics and home care. Hospitals and clinics use these devices for proper diagnosis and follow up of patients with respiratory ailments. It was observed in 2023 that at least 70% of the hospitals located in the developed countries have already connected advanced spirometers and peak flow meters for diagnosis processes. In home care settings, the advantage of the modern devices is the fact that they can be used by the patients themselves, and thus the home health care market of the respiratory devices reached $4.5 billion by the last of the year 2023. Some of these companies include Philips healthcare and Resmed which operate in this market and have published their notable growth rates owing to the rising needs of their respiratory health technologies. This is also due to the constant need for portable devices and the growing awareness of how important Respiratory Health Management.

By Indication 

Based on indication, COPD is the major contributor to the revenue in the COPD & asthma diagnostic and monitoring devices market in which the revenue share stands at more than 75.8%. Several critical factors explain the increasing need for COPD diagnostic and monitoring devices as opposed to the demand for asthma diagnostic devices. Even though the total number of individuals diagnosed with chronic obstructive pulmonary disease (COPD) is over 200 million and it is one of the leading causes of morbidity and mortality around the globe, a significant proportion of this figure is left undiagnosed until the later stages of the disease. This in turn creates a very large demand for such diagnostic methods as well as devices for monitoring the progress of the disease at earlier stages. 

On the other hand, approximately 300 million live with asthma, with inhaled medications becoming a well-accepted treatment for many patients, and thus lessening the urgent need for diagnosis devices. The resultant population aging contributes to the increased population with COPD especially in countries with a history of high cigarette smoking population. Also, there are social and economic costs of the disease COPD, and yearly billions are spent in the health care system and loss of productivity, therefore health care systems try to buy better and advanced diagnostic and monitoring systems to control the disease better.

The COPD & asthma diagnostic and monitoring devices market are characterized by an increasing trend of technological innovation and adoption of digital health solutions. Management of these diseases often calls on the services of portable spirometers and peak flow meters that are easily within reach by the patients. There is also an increase in the number of adherents who now use smart inhalers and mobile health applications that enable them to receive real time information and enhance treatment adherence. The trend towards the development of precise and user-friendly devices for both hospital and home care is gaining momentum with industries focusing on producing such devices. The global market of the respiratory monitoring devices is expected to register a strong increase with COPD devices taking the lead owing to the nature of the ailment being prevalent and complex. This spice is added to the ole as a consequence of policies put into consideration by governments aiming at diminishing the burden associated with the respiratory diseases and further progression to improve patient health care outcomes.

By End Users

Hospitals and clinics retain their dominance in the COPD & asthma diagnostic and monitoring devices market as the foremost consumers of the market, accounting for more than 63.9% of the market share. This dominance is primarily because of the active infrastructure and resources that they have when compared to other healthcare institutions. The World Health Organization estimates that around 300 million people suffer from global prevalence of asthma. On the other hand, there are approximately 210 million people enduring chronic obstructive pulmonary disease (COPD). As a result, there is a growing need for advanced diagnostic and monitoring devices, most often located within clinics and hospitals. Such institutes have specialized instruments, like the spirometers, the peak flow meters, and the blood gas analyzers which provide efficient diagnostics and control of diseases of the respiratory system. Moreover, qualified healthcare specialists work there, who are able to decipher interferometric pictures and make charge therapy effectively. In 2023, citing the World Health Organization, respiratory diseases take the position of the leading health factors ruled out to the population stress and due to that, it brings the need for diagnostic and monitoring devices that are on clinical standard level.

In addition, the hospitals and clinics have a strong position in COPD & asthma diagnostic and monitoring devices market due to the fact that they partake in the provision of health care services. In 2023, a study was published estimating that around 70% of all diagnoses of chronic obstructive pulmonary disease and of asthma were performed in hospitals or polyclinics. Further, these establishments administer over 90 million spirometry test procedures each year, which lies at the heart of respiratory diagnosis. The huge patient turnover in the hospitals, most of which are attributed to respiratory diseases, also helps in the steady market for diagnostic equipment. Furthermore, hospitals and clinics are also places where some practitioners and other health workers are trained with the understanding that they will engage in practice that requires such high standard diagnostics. Hospitals, being the integrating social businesses of the future, are incorporating modern technologies into their infrastructure such as digital health systems to track patients and provide a wider range of medical services than small health care facilities can offer. 

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

Over the years, the global COPD & asthma diagnostic and monitoring devices market growth market has achieved notable levels in the Asia Pacific, North America and Europe regions. However, it is the Asia Pacific region that leads with a lion market share of over 32.1%. This dominance is mainly led by high rates of respiratory disease across countries in this region due to increasing pollution and high population having smoking addiction in countries such as China and India. It is reported, from the study, that there are around about one hundred million Chronic Obstructive Pulmonary Disease (COPD) patients in China and this country is experiencing a huge number of asthma cases as well. Pressure asthma is also very high in India, with estimates of over 30 million asthma patients. The region’s market position is bolstered further by the advanced medical facilities available in nations such as Japan and South Korea. In Japan alone, there are over six million asthma patients in the country with asthma and its government is very aggressive willing to offer funds to support invention of new diagnosis devices. The method rather easy explains why there is always a increase in the sale of new technologies, portable spirometers, smart inhalers to the patients with opposite methods.

The North America COPD & asthma diagnostic and monitoring devices market is driven by high emphasis on innovations and technology related to healthcare. The United States is the most central to the regional for being host to leading companies in the medical devices industry. The country has a sizable demographic which suffers from respiratory diseases, with over 25 million people diagnosed with asthma and approximately 16 million adult patients suffering from COPD. The high prevalence of diseases has stimulated the need for advanced diagnostic and monitoring systems including telemedicine applications and AI-based predictive analytics. Canadian market is also growing at a rapid pace with the help of government programs aiming to prevent moderate coverage of CHF heart failure and reduce hospital readmissions through early diagnosis and timely patient care. North American market is also helped by the fact that there are favorable reimbursement policies in place and the need for diagnosis of respiratory diseases is quite high and therefore supporting the sale of advanced equipment.

On the contrary, instead, Europe COPD &asthma diagnostic and monitoring devices market seems to be developing in line with the stringent regulatory requirements and the emphasis on patient safety and effective disease control. The region is experiencing an encouraging growth in the market for non-invasive imaging techniques and devices for home monitoring due to the aging population and increased emphasis on preventive medicine. Asthma is quite prevalent in the United Kingdom where more than 5 million people are internally diagnosed with asthma and the country has constantly invested on research towards addressing chronic respiratory diseases. Germany consistently works to integrate digital health technologies into practice, particularly in the area of respiratory care. Chronic obstructive pulmonary disease in patients in France is also supported by various awareness campaigns on patient education and self-management. All over Europe, health technology applications developed by health institutions and technology companies are revolutionizing the management of COPD and asthma disease in patients.

Top Players in the Global COPD & Asthma Diagnostic and Monitoring Devices Market 

• Becton Dickinson And Company
• Dragerwerk Ag & Co. KGAA
• Getinge AB
• Invacare Corporation
• Masimo Corporation
• Medtronic Plc
• Nihon Kohden Corporation
• Smiths Medical
• Vyaire Medical
• Other Prominent Players

Market Segmentation Overview:

By Diagnostic Devices

• Spirometers
• Electrocardiograms
• FeNO Test analyzer
• Arterial blood gas analyzer (ABG)
• Polysomnography devices
• Peak flow meters
• Others

By Monitoring Devices

• Pulse oximeters
• Capnographs
• Asthma monitors
• Portable tabletop pulse oximeter
• Wearable devices
• Others

By Consumables and Accessories

• Masks
• Spirometry accessories
• Polysomnography accessories
• Peak flow meter accessories
• Pulse oximeter sensors
• Capnography accessories
• Others

By Indication

• Asthma
• COPD

By End User

• Hospitals and clinics
• Home care settings
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America